272 related articles for article (PubMed ID: 28544403)
1. Serine protease inhibitor Kazal type 1 (SPINK1) downregulates E-cadherin and induces EMT of hepatoma cells to promote hepatocellular carcinoma metastasis via the MEK/ERK signaling pathway.
Ying HY; Gong CJ; Feng Y; Jing DD; Lu LG
J Dig Dis; 2017 Jun; 18(6):349-358. PubMed ID: 28544403
[TBL] [Abstract][Full Text] [Related]
2. Serine protease inhibitor Kazal type 1 promotes epithelial-mesenchymal transition through EGFR signaling pathway in prostate cancer.
Wang C; Wang L; Su B; Lu N; Song J; Yang X; Fu W; Tan W; Han B
Prostate; 2014 May; 74(7):689-701. PubMed ID: 24619958
[TBL] [Abstract][Full Text] [Related]
3. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
Feng XJ; Pan Q; Wang SM; Pan YC; Wang Q; Zhang HH; Zhu MH; Zhang SH
Tumour Biol; 2016 Aug; 37(8):11457-67. PubMed ID: 27010469
[TBL] [Abstract][Full Text] [Related]
4. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma.
Shek FH; Luo R; Lam BYH; Sung WK; Lam TW; Luk JM; Leung MS; Chan KT; Wang HK; Chan CM; Poon RT; Lee NP
Cell Oncol (Dordr); 2017 Oct; 40(5):443-456. PubMed ID: 28631187
[TBL] [Abstract][Full Text] [Related]
5. STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Wang Z; Qu L; Deng B; Sun X; Wu S; Liao J; Fan J; Peng Z
Sci Rep; 2016 Sep; 6():33205. PubMed ID: 27628214
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CSN6 promotes the epithelial-mesenchymal transition and predicts poor prognosis in hepatocellular carcinoma.
Xu M; Zhen L; Lin L; Wu K; Wang Y; Cai X
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):340-348. PubMed ID: 31422034
[TBL] [Abstract][Full Text] [Related]
7. TMPRSS4 facilitates epithelial-mesenchymal transition of hepatocellular carcinoma and is a predictive marker for poor prognosis of patients after curative resection.
Wang CH; Guo ZY; Chen ZT; Zhi XT; Li DK; Dong ZR; Chen ZQ; Hu SY; Li T
Sci Rep; 2015 Jul; 5():12366. PubMed ID: 26190376
[TBL] [Abstract][Full Text] [Related]
8. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
[TBL] [Abstract][Full Text] [Related]
9. ERK pathway activation contributes to the tumor-promoting effects of hepatic stellate cells in hepatocellular carcinoma.
Xie YX; Liao R; Pan L; Du CY
Immunol Lett; 2017 Aug; 188():116-123. PubMed ID: 28668554
[TBL] [Abstract][Full Text] [Related]
10. MCM6 promotes metastasis of hepatocellular carcinoma via MEK/ERK pathway and serves as a novel serum biomarker for early recurrence.
Liu M; Hu Q; Tu M; Wang X; Yang Z; Yang G; Luo R
J Exp Clin Cancer Res; 2018 Jan; 37(1):10. PubMed ID: 29357919
[TBL] [Abstract][Full Text] [Related]
11. [Hepatic stellate cell conditioned medium induces proliferation and epithelial-mesenchymal transition via activating ERK1/2 signaling pathway in hepatoma cells].
Xie Y; Liao R; Pan L; Fan K; Peng C; Du C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):210-4. PubMed ID: 29762991
[TBL] [Abstract][Full Text] [Related]
12. ECM1 promotes migration and invasion of hepatocellular carcinoma by inducing epithelial-mesenchymal transition.
Chen H; Jia W; Li J
World J Surg Oncol; 2016 Jul; 14(1):195. PubMed ID: 27460906
[TBL] [Abstract][Full Text] [Related]
13. Lack of hepatic stimulator substance expression promotes hepatocellular carcinoma metastasis partly through ERK-activated epithelial-mesenchymal transition.
Jia XW; Li ZW; Dong LY; Sun GY; Wang X; Gao J; Li YP; Wu Y; An W
Lab Invest; 2018 Jul; 98(7):871-882. PubMed ID: 29497174
[TBL] [Abstract][Full Text] [Related]
14. MTBP Promotes the Invasion and Metastasis of Hepatocellular Carcinoma by Enhancing the MDM2-Mediated Degradation of E-Cadherin.
Lu S; Zhou W; Wei H; He L; Li L
Dig Dis Sci; 2015 Dec; 60(12):3681-90. PubMed ID: 26280083
[TBL] [Abstract][Full Text] [Related]
15. Chemokine ligand 20 enhances progression of hepatocellular carcinoma via epithelial-mesenchymal transition.
Hou KZ; Fu ZQ; Gong H
World J Gastroenterol; 2015 Jan; 21(2):475-83. PubMed ID: 25593462
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of ZEB1 protein in patients with hepatocellular carcinoma.
Zhou YM; Cao L; Li B; Zhang RX; Sui CJ; Yin ZF; Yang JM
Ann Surg Oncol; 2012 May; 19(5):1700-6. PubMed ID: 21584833
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of RFX1 predicts poor prognosis of patients with small hepatocellular carcinoma.
Liu Y; Jiang P; Wang G; Liu X; Luo S
Eur J Surg Oncol; 2018 Jul; 44(7):1087-1093. PubMed ID: 29764705
[TBL] [Abstract][Full Text] [Related]
18. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1.
Zhao XL; Sun T; Che N; Sun D; Zhao N; Dong XY; Gu Q; Yao Z; Sun BC
J Cell Mol Med; 2011 Mar; 15(3):691-700. PubMed ID: 20219012
[TBL] [Abstract][Full Text] [Related]
19. STAT3 cooperates with Twist to mediate epithelial-mesenchymal transition in human hepatocellular carcinoma cells.
Zhang C; Guo F; Xu G; Ma J; Shao F
Oncol Rep; 2015 Apr; 33(4):1872-82. PubMed ID: 25653024
[TBL] [Abstract][Full Text] [Related]
20. Methionine Sulfoxide Reductase B1 Regulates Hepatocellular Carcinoma Cell Proliferation and Invasion via the Mitogen-Activated Protein Kinase Pathway and Epithelial-Mesenchymal Transition.
He Q; Li H; Meng F; Sun X; Feng X; Chen J; Li L; Liu J
Oxid Med Cell Longev; 2018; 2018():5287971. PubMed ID: 29861830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
